Status: Not yet recruiting
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
This is an open-label, dose-escalation and dose-expansion Phase I /II clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with malignant solid tumors.
Participants needed: 72
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Immorna Biotherapeutics, Inc.Updated: Mar 24, 2026
Eligibility criteria
Male or female patients, aged 18 to 75 years; [+2]
Known or suspected allergy to the ingredients of the study drug or its analogues... [+2]